Clinical trials
Immunotherapy clinical trials
Below are recruiting immunotherapy clinical trials, each written for real people, not researchers. We’re tracking 747 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06855121Recruiting
Norwegian immunotherapy study for multiple myeloma patients
This study collects information from people with multiple myeloma, plasma cell leukemia, or AL-amyloidosis who are about to start a new type of immunotherapy. It helps doctors understand how these treatments work in real life.
ArendalAges 18 years+ - NCT06840834RecruitingPhase 2
New drug for mesothelioma that has returned after prior treatment
This trial tests a drug called ivonescimab for people with pleural mesothelioma (a cancer of the lung lining) that has grown back after earlier immunotherapy and chemotherapy. The drug may help by blocking a protein that tumors use to hide from the immune system, possibly slowing or shrinking the cancer.
BesançonAges 18 years+ - NCT05810402Recruiting
Testing immunotherapy for advanced liver cancer using blood tests
This study looks at how well immune-checkpoint therapy (a PD-1 or PD-L1 immunotherapy) works for advanced liver cancer, using “liquid biopsy” blood testing to guide or monitor care. It may help your team better track your cancer and response without needing repeated tissue biopsies.
MontpellierAges 18 years+ - NCT06421415Recruiting
Long-term effects of allergy shots in children
This study looks at how well allergy shots or drops work over the long term in children who received this treatment at Odense University Hospital. It aims to understand if the benefits last for years after treatment ends.
Odense, Odense CAges 4–18 - NCT06834165RecruitingPhase 4
Study of neffy vs. epinephrine shots for allergic reactions
This study compares a new nasal spray (neffy) to a standard epinephrine shot for treating severe allergic reactions during food challenges or allergy immunotherapy. It aims to see if the spray works as well and is safe.
La Jolla, CaliforniaAges 4 years+ - NCT06833229Recruiting
Can a PET scan predict if immunotherapy is working?
This study uses a special PET-CT scan early in your treatment to see if immunotherapy (with or without chemotherapy) is working against your advanced lung cancer. The goal is to find out faster if the treatment is helping.
NiceAges 18 years+ - NCT06826079RecruitingPhase 2
Sorbitol plus chemo and immunotherapy for advanced gastric cancer
This trial tests adding sorbitol to standard chemotherapy and an immunotherapy drug (tirellizumab) for people with locally advanced stomach cancer. The goal is to see if this combination is safe and helps shrink tumors before surgery.
Wuhan, HubeiAges 18–70 - NCT05862259Recruiting
Immunotherapy as first treatment for advanced stage IV cancers
This study looks at whether immune checkpoint inhibitors given as the first treatment work well and are safe for people with advanced (stage IV) solid tumors. You might qualify if you can take study treatment reliably and your cancer type and health match the study rules.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT06823375RecruitingPhase 2
Radiation plus immunotherapy for liver cancer with major vein clot
This trial tests adding radiation (SBRT) to a combination of immunotherapy drugs (atezolizumab and bevacizumab) for people with liver cancer that has spread into the main portal vein. It aims to see if this approach can shrink tumors and improve outcomes.
Hong KongAges 18 years+ - NCT06816966Enrolling by invitationPhase 2
Chemo-immunotherapy with split radiation for extensive-stage lung cancer
This trial tests a combination of chemotherapy, immunotherapy, and a special type of radiation given in split sessions for people with extensive-stage small cell lung cancer. The goal is to see if this approach can help control the cancer better.
Fuzhou, FujianAges 18 years+ - NCT06816927RecruitingPhase 2
Immunotherapy trial for glioblastoma with nivolumab and relatlimab
This trial tests whether two immunotherapy drugs, nivolumab and relatlimab, can help treat glioblastoma (GBM), a type of brain tumor. It is for people newly diagnosed or who haven't had radiation or chemotherapy yet and are scheduled for surgery.
New York, New YorkAges 18 years+ - NCT06805305RecruitingPhase 2
Immunotherapy for newly diagnosed glioblastoma
This trial tests a new personalized immunotherapy (DOC1021) for people with newly diagnosed glioblastoma. The treatment uses your own immune cells to attack the tumor and is given after surgery and with standard chemotherapy and radiation.
Gilbert, ArizonaAges 18 years+ - NCT06810609RecruitingPhase 2
Immunochemotherapy, surgery, and durvalumab for stage III lung cancer
This trial tests a combination of immunotherapy, chemotherapy, and either surgery or radiation for people with stage IIIA or IIIB non-small cell lung cancer. The goal is to see if adding the drug durvalumab after standard treatment helps control the cancer better.
Freiburg im Breisgau, Baden-WurttembergAges 18–74 - NCT06801067RecruitingPhase 1
Testing SER-155 for immunotherapy-related diarrhea
This trial tests an investigational oral medication (SER-155) for people whose diarrhea is caused by immunotherapy. It aims to calm the gut and reduce symptoms without needing stronger drugs.
Basking Ridge, New JerseyAges 18 years+ - NCT06794775RecruitingPhase 3
Immunotherapy before surgery for stage III melanoma
This trial is for people with stage III melanoma that can be surgically removed. It compares one immunotherapy drug to a combination of two, to see which works better before surgery.
GothenburgAges 18 years+ - NCT06780475Recruiting
Lab test for a new Merkel cell cancer treatment
This trial is testing a lab method to see if a specific type of immunotherapy can work against Merkel cell carcinoma. It may help find new treatment options for people with this skin cancer.
Boulogne-BillancourtAges 18 years+ - NCT06776861Recruiting
Radiation plus immunotherapy for advanced breast cancer
This study looks at combining radiation therapy with immunotherapy for advanced breast cancer that has spread or cannot be surgically removed. The goal is to see if adding radiation after treatment helps improve outcomes.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06777719RecruitingPhase 1
A study of immune cells to prevent kidney rejection
This trial tests if giving you back specially grown immune cells (called Tregs) made from your own blood can help your body accept a new kidney from a living donor with less rejection. It is for people who are ready for a first kidney transplant.
NantesAges 18–99 - NCT06771791RecruitingPhase 3
Apple oral immunotherapy trial for birch pollen and apple allergy
This trial tests if eating small amounts of raw apple can help people with birch pollen allergy who also have mouth itching or swelling from apples. You will be given gradually increasing doses of apple to see if your allergy improves.
Strasbourg, FranceAges 18 years+ - NCT06770582RecruitingPhase 2
Adding immunotherapy to radiation for bladder cancer
This trial tests whether adding the immunotherapy drug pembrolizumab to radiation therapy works as well as or better than the usual chemotherapy given with radiation for a type of bladder cancer that has not invaded the muscle. It is for people whose cancer came back or has high-risk features and who would otherwise need to have their bladder removed.
Tucson, ArizonaAges 18 years+ - NCT06762769RecruitingPhase 2
Isatuximab and iberdomide for high-risk smoldering myeloma
This trial is testing a combination of two drugs, isatuximab and iberdomide, to help people with high-risk smoldering myeloma avoid progressing to active multiple myeloma. It aims to see if this immunotherapy approach can delay or prevent the need for stronger treatments.
LondonAges 18 years+ - NCT06771518RecruitingPhase 2
Study combining chest radiation and immunotherapy for lung cancer
This study tests whether adding radiation to the chest area can improve the effectiveness of maintenance immunotherapy (atezolizumab) in patients with extensive-stage small cell lung cancer who have responded well to initial treatment.
Rome, RomeAges 18 years+ - NCT06768931RecruitingPhase 2
Combination therapy before surgery for triple-negative breast cancer
This trial tests adding an immunotherapy drug to standard chemotherapy before surgery for triple-negative breast cancer. The goal is to see if this combination works better than chemotherapy alone.
Lanzhou, GansuAges 18 years+ - NCT06755567Recruiting
Testing MRI to predict immunotherapy and chemo results
This trial is studying how MRI images can help predict response to a combination of chemotherapy and immunotherapy before surgery for head and neck cancer. It aims to improve treatment planning for patients with this type of cancer.
Guangzhou, GuangdongAges 18–80
Hear when a new Immunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for immunotherapy?
- Yes. Clin2 currently lists 747 recruiting immunotherapy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a immunotherapy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a immunotherapy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.